Professional Academic

Professional Academic

Clinical base

Thermotherapy Special Topic

Clinical Application - Internal Medicine

Clinical Application - Surgery

Animal Experimentation

Safety assessment of animal experiments for intraperitoneal thermal perfusion therapy    
——

 

Objective

　　To explore the effects of coelom continued circulatory hyperthermia perfusion (CCCHP) on the vital signs of experimental animals and the organs in the abdominal cavity at different temperatures, in order to find the optimal treatment temperature and effective temperature control methods.
 

Methods

　　Dogs were selected as experimental animals, and a CCCHP animal model was established using an intraperitoneal circulation perfusion hyperthermia machine. Each group of animals underwent CCCHP three times at abdominal temperatures of 41°C (divided into normal saline group and cisplatin group), 42°C (normal saline group), and 43°C (normal saline group) for 1 hour each time, with a 2-day interval. The vital signs of the dogs, thermometer readings, and data from the thermal perfusion machine panel were recorded. Peripheral blood was drawn for testing before each CCCHP and 24 hours after each CCCHP. After three CCCHP sessions, two dogs from each group were euthanized at 24 hours and 2 weeks, and the morphological changes of the internal organs were observed through laparotomy, with liver, kidney, and other organs taken for pathological examination.
 

Results

　　Three sessions of CCCHP at an abdominal temperature of 41°C had no significant effect on the vital signs and liver and kidney function of the dogs, with only mild damage to the liver, kidney, spleen, and intestinal tissues; three sessions of CCCHP at 41°C combined with cisplatin also did not cause significant effects on the normal physiological functions of the dogs; after three sessions of CCCHP at 42°C and 43°C, there were varying degrees of effects on the vital signs and liver and kidney function of the dogs, with different degrees of damage to the liver, kidney, spleen, and intestinal tissues.
 

Conclusion

　　Three sessions of CCCHP at an abdominal temperature of 41°C for 1.0 hour each time is safe and feasible, and can be considered a relatively safe treatment temperature for CCCHP combined with chemotherapy; under the same conditions, 42°C may cause mild damage to important abdominal organs in dogs, and is not recommended as a routine treatment temperature for CCCHP; 43°C may cause severe damage to the normal physiological functions of dogs, and is not suitable as a treatment temperature for CCCHP.
 

Intraperitoneal constant temperature circulatory hyperthermia perfusion chemotherapy - experimental dogs

Intraperitoneal constant temperature circulatory hyperthermia perfusion chemotherapy - experimental mice

 

Safety assessment of animal experiments for intraperitoneal thermal perfusion therapy
 
　　 Objective:To explore the effects of coelom continued circulatory hyperthermia perfusion (CCCHP) at different temperatures on the vital signs of experimental animals and the organs in the abdominal cavity, in order to find the optimal treatment temperature and effective temperature control methods.
 
　　 Methods:Dogs were selected as experimental animals, and a CCCHP animal model was established using an intraperitoneal circulation perfusion hyperthermia machine. Each group of animals underwent CCCHP three times at abdominal temperatures of 41°C (divided into normal saline group and cisplatin group), 42°C (normal saline group), and 43°C (normal saline group) for 1 hour each time, with a 2-day interval. The vital signs of the dogs, thermometer readings, and data from the thermal perfusion machine panel were recorded. Peripheral blood was drawn for examination before each CCCHP and 24 hours after each CCCHP. After three CCCHP sessions, two dogs from each group were euthanized at 24 hours and 2 weeks, and the morphological changes of the internal organs were observed through laparotomy, with liver, kidney, and other organs taken for pathological examination.
 
　　 Results:Three sessions of CCCHP at an abdominal temperature of 41°C had no significant effect on the vital signs and liver and kidney function of the dogs, with only mild damage to the liver, kidney, spleen, and intestinal tissues; three sessions of CCCHP at 41°C combined with cisplatin also did not cause significant effects on the normal physiological functions of the dogs; after three sessions of CCCHP at 42°C and 43°C, there were varying degrees of effects on the vital signs and liver and kidney function of the dogs, with different degrees of damage to the liver, kidney, spleen, and intestinal tissues.
 
　　 Conclusion:Three sessions of CCCHP at an abdominal temperature of 41°C for 1.0 hour each time is safe and feasible, and can be considered a relatively safe treatment temperature for CCCHP combined with chemotherapy; at 42°C under the same conditions, there will be mild damage to the important abdominal organs of the dogs, and it is not recommended as a routine treatment temperature for CCCHP; at 43°C under the same conditions, there will be severe damage to the normal physiological functions of the dogs, making it unsuitable as a treatment temperature for CCCHP.
 
GD
GD
GD
 
 
 
GD
GD
GD
 
 
 
GD
GD
GD